Unknown

Dataset Information

0

Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T

ABSTRACT:

SUBMITTER: Galli E 

PROVIDER: S-EPMC12378911 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
| S-EPMC9904360 | biostudies-literature
Unknown Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells.
| S-EPMC11999194 | biostudies-literature
Unknown Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
| S-EPMC10031882 | biostudies-literature
Unknown Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.
| S-EPMC12848367 | biostudies-literature
Unknown Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.
| S-EPMC12848356 | biostudies-literature
Unknown Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL.
| S-EPMC9278282 | biostudies-literature
Unknown Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.
| S-EPMC12155625 | biostudies-literature
Unknown Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.
| S-EPMC9302339 | biostudies-literature
Unknown Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
| S-EPMC7976586 | biostudies-literature
Unknown Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
| S-EPMC11964843 | biostudies-literature